INTRODUCTION Sexual desire is controlled by brain systems involved in sexual excitation and inhibition. Hypoactive sexual desire disorder (HSDD) may result from hypofunctional excitation, hyperfunctional inhibition, or some mix of the two. AIM This study aimed to identify neurochemical and neuroanatomical systems involved in sexual excitation and inhibition, their role during normal, and hypo...

Hypoactive sexual desire disorder (HSDD) is defined as a deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The dysfunction cannot be better accounted for by another psychiatric disorder (except another sexual dysfunction) and must not be due exclusively to the physiological effects of a substance or a general medica...

The constant domination of customer requirements has forced survival industries to become more and more agile. As a response to this necessity, the Holonic Manufacturing System (HMS) project proposed the principles of a re-configurable system constructed of autonomous and cooperative elements. The desired degree of response to market needs can be achieved exploring concepts from the holonic par...

There have been several products developed for male sexual dysfunction. However, developing agents for female sexual dysfunction is lagging behind for various reasons. Sildenafil citrate (Viagra) and Tadalafil (Cialis), which have been prescribed for male sexual function disorders, are known to act on vessels.[1] On the other hand, flibanserin is thought to act on brain. Flibanserin has been ap...

Abstract Introduction Data on the role of prolactin (PRL) in physiologic range female sexual response are scanty. Objective To investigate association between PRL and function as assessed by Female Sexual Function Index (FSFI). We explored presence a cut-off level able to identify Hypoactive Desire Disorder (HSDD). Methods N=264 pre- post-menopausal women consulting for FSD sexually active were...

On August 18, 2015, the U.S. Food and Drug Administration (FDA) approved a first in class multifunctional serotonin agonist and antagonist medication, flibanserin, for the treatment of generalized acquired hypoactive sexual desire disorder (HSDD) in premenopausal women. This approval was surrounded by political posturing that has resulted in naysayers attacking the science based on their feelin...

Introduction. Psychopathological origins of personally distressing, hypoactive sexual desire disorder (HSDD) in women are unknown, but are generally attributed to an inhibitory neural regulator, serotonin (5-HT). Flibanserin, a 5-HT1A agonist and 5-HT2A antagonist, shows promise as a treatment for HSDD. Aim. To test the hypothesis that female marmoset sexual behavior is enhanced by flibanserin ...

INTRODUCTION A historic belief was that testosterone was the "hormone of desire." However, recent data, which show either minimal or no significant correlation between testosterone levels and women's sexual desire, suggest that nonhormonal variables may play a key role. AIM To compare women with hypoactive sexual desire disorder (HSDD) and those with the recently proposed more symptomatic des...

OBJECTIVE Evaluation of the use of testosterone therapy for hypoactive sexual desire disorder (HSDD) after oophorectomy has mostly involved women treated with oral estrogen preparations. We investigated the efficacy and safety of a testosterone patch in surgically menopausal women receiving concurrent transdermal estrogen. DESIGN Women with HSDD after oophorectomy, for whom this was a concern...